A composition comprising CRH, CRH binding protein (CRH-BP), alpha-2 macroglobulin (A2M) and alpha-melanocyte stimulating hormone (alpha-MSH) for use in treatment of a medical condition selected from the list consisting of an ulcer or soft tissue damage.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K 38/34 - Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
The present invention relates to a CRH formulation and to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.
A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
The present invention relates to a CRH formulation having improved stability/ efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
4.
FORMULATION COMPRISING CRH AND ALPHA - 2 - IMMUNOGLOBULIN
The present invention relates to a CRH formulation having improved stability/ efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
The invention relates to methods for reducing the plasma levels of TNF, VEGF, anti-inflammatory cytokines and chemokines. The invention also relates to methods and compositions for use in the treatment of a disorder characterised by abnormally high TNF and/or VEGF levels.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 13/00 - Drugs for disorders of the urinary system
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K 38/34 - Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
The present invention describes a pharmaceutical composition comprising the opioid receptor antagonist naltrexone, and a) a serum composition obtained from a mamma!, preferably a goat, after challenge with an immunogen; or b) a serum composition obtained from a naÊve mammal, preferably a goat; or c) a POMC peptide; or d) a CRF peptide. The composition is useful for the treatment of diseases such as HIV, certain cancers, and multiple sclerosis, among others. Methods of treatment of such diseases are also described.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Pharmaceutical compositions comprising serum obtained from non-immunised mammals, particularly ungulates, and more particularly goats, are described, together with methods for their preparation. The compositions are particularly useful for the treatment of multiple sclerosis, optic neuritis, rheumatoid arthritis, and HIV, but have applicability to a wide range of conditions.
Methods of treatment of various non-demyelinating and demyelinating neural disorders are provided, comprising administering a serum composition obtained from a goat after challenge with an HIV immunogen, also called "Aimspro". Also provided are methods of treatment of certain autoimmune disorders (e.g. psoriasis) using such a composition.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/00 - Drugs for immunological or allergic disorders
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and substances for human and veterinary use. Medical, veterinary and diagnostic devices, instruments and apparatus; sprays, dispensers, applicators, syringes and devices for the delivery of pharmaceuticals; parts, fittings and refills for the aforesaid goods. Laboratory research services; pharmaceutical research and development services; biotechnological, chemical and biochemical research services; contract research services. Medical, veterinary and pharmaceutical advisory and consultancy services.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and substances for human and veterinary use. Medical, veterinary and diagnostic devices, instruments and apparatus; sprays, dispensers, applicators, syringes and devices for the delivery of pharmaceuticals; parts, fittings and refills for the aforesaid goods. Laboratory research services; pharmaceutical research and development services; biotechnological, chemical and biochemical research services; contract research services. Medical, veterinary and pharmaceutical advisory and consultancy services.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and substances for human and veterinary use. Medical, veterinary and diagnostic devices, instruments and apparatus; sprays, dispensers, applicators, syringes and devices for the delivery of pharmaceuticals; parts, fittings and refills for the aforesaid goods. Laboratory research services; pharmaceutical research and development services; biotechnological, chemical and biochemical research services; contract research services. Medical, veterinary and pharmaceutical advisory and consultancy services.
